High-Risk Medication Prescriptions in Primary Care for Women Without Documented Contraception

References

1. 1.↵
   1. Mitchell AA,
   2. Gilboa SM,
   3. Werler MM,
   4. et al

   . Medication use during pregnancy, with particular focus on prescription drugs: 1976–2008. Am J Obstet Gynecol 2011;205:51.e1–8.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Egen-Lappe V,
   2. Hasford J

   . Drug prescription in pregnancy: analysis of a large statutory sickness fund population. Eur J Clin Pharmacol 2004;60:659–66.

   OpenUrlCrossRefPubMedWeb of Science
3. 3.↵
   1. Daw JR,
   2. Hanley GE,
   3. Greyson DL,
   4. Morgan SG

   . Prescription drug use during pregnancy in developed countries: a systematic review. Pharmacoepidemiol Drug Saf 2011;20:895–902.

   OpenUrlPubMed
4. 4.↵
   1. Andrade SE,
   2. Gurwitz JH,
   3. Davis RL,
   4. et al

   . Prescription drug use in pregnancy. Am J Obstet Gynecol 2004;191:398–407.

   OpenUrlCrossRefPubMedWeb of Science
5. 5.↵
   1. Lee E,
   2. Maneno MK,
   3. Smith L,
   4. et al

   . National patterns of medication use during pregnancy. Pharmacoepidemiol Drug Saf 2006;15:537–45.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Schwarz EB,
   2. Maselli J,
   3. Norton M,
   4. Gonzales R

   . Prescription of teratogenic medications in United States ambulatory practices. Am J Med 2005;118:1240–9.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Schwarz EB,
   2. Postlethwaite DA,
   3. Hung YY,
   4. Armstrong MA

   . Documentation of contraception and pregnancy when prescribing potentially teratogenic medications for reproductive-age women. Ann Intern Med 2007;147:370–6.

   OpenUrlCrossRefPubMedWeb of Science
8. 8.↵
   1. Fritsche MD,
   2. Ables AZ,
   3. Bendyk H

   . Opportunities missed: improving the rate of contraceptive counseling or provision when prescribing reproductive-aged women potentially teratogenic medications in a family medicine resident clinic. Contraception 2011;84:372–6.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Schwarz EB,
   2. Santucci A,
   3. Borrero S,
   4. Akers AY,
   5. Nikolajski C,
   6. Gold MA

   . Perspectives of primary care clinicians on teratogenic risk counseling. Birth Defects Res A Clin Mol Teratol 2009;85:858–63.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Pace LE,
    2. Schwarz EB

    . Balancing act: safe and evidence-based prescribing for women of reproductive age. Womens Health (Lond) 2012;8:415–25.

    OpenUrl
11. 11.↵
    1. Garcia-Bournissen F,
    2. Tsur L,
    3. Goldstein LH,
    4. et al

    . Fetal exposure to isotretinoin-an international problem. Reprod Toxicol 2008;25:124–8.

    OpenUrlCrossRefPubMed
12. 12.↵
    iPledge: committed to pregnancy prevention. 2016. Available from: https://www.ipledgeprogram.com/iPledgeUI/home.u. Accessed September 16, 2018.
13. 13.↵
    Isotretinoin (marketed as Accutane) capsule information. United States Department of Health and Human Services, 2007. Available from: https://www.fda.gov/Drugs/DrugSafety/ucm094305.htm. Accessed September 16, 2018.
14. 14.↵
    1. Danielsson B,
    2. Wikner BN,
    3. Kallen B

    . Use of ondansetron during pregnancy and congenital malformations in the infant. Reprod Toxicol 2014;50:134–7.

    OpenUrlCrossRefPubMed
15. 15.↵
    1. Carstairs SD

    . Ondansetron use in pregnancy and birth defects: a systematic review. Obstet Gynecol 2016;127:878–83.

    OpenUrlPubMed
16. 16.↵
    POISONDEX (Micromedex 2.0). 2018. Available from: https://www.micromedexsolutions.com/micromedex2/librarian/. Accessed March 12, 2018.